WO2017074036A3 - 암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템 - Google Patents

암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템 Download PDF

Info

Publication number
WO2017074036A3
WO2017074036A3 PCT/KR2016/012108 KR2016012108W WO2017074036A3 WO 2017074036 A3 WO2017074036 A3 WO 2017074036A3 KR 2016012108 W KR2016012108 W KR 2016012108W WO 2017074036 A3 WO2017074036 A3 WO 2017074036A3
Authority
WO
WIPO (PCT)
Prior art keywords
information
cancer
nucleotide sequence
survival
genomic nucleotide
Prior art date
Application number
PCT/KR2016/012108
Other languages
English (en)
French (fr)
Other versions
WO2017074036A2 (ko
Inventor
김주한
Original Assignee
주식회사 싸이퍼롬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 싸이퍼롬 filed Critical 주식회사 싸이퍼롬
Priority to JP2018542073A priority Critical patent/JP6681475B2/ja
Priority to EP16860219.1A priority patent/EP3396573A4/en
Priority to CN201680062975.4A priority patent/CN108475300B/zh
Priority to US15/771,288 priority patent/US20180312928A1/en
Priority claimed from KR1020160140346A external-priority patent/KR101949286B1/ko
Publication of WO2017074036A2 publication Critical patent/WO2017074036A2/ko
Publication of WO2017074036A3 publication Critical patent/WO2017074036A3/ko

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 암 유전체 염기서열 변이와 환자 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템에 관한 것으로, 보다 구체적으로 암 유전체 염기서열 변이 중 합성암생존 (Synthetic Cancer Survival) 유전자의 변이 정보를 이용한 맞춤형 항암 치료 약물 선택 방법 및 시스템에 관한 것이다. 본 발명의 암 유전체 돌연변이와 환자 생존 정보, 또는 암세포나 조직의 침윤 또는 전이 능력 평가를 이용한 맞춤형 항암 치료 방법 및 시스템은 암 유전체 염기서열 변이와 암 생존 및 전이 정보로부터 도출한 합성암생존 유전자 쌍의 변이 분석을 통하여 개인별로 치료 효과 및 예후가 좋은 항암 치료 약물을 효과적으로 선택할 수 있는 기술로서 신뢰도가 높으며, 신속하고 간단하게 관련 정보를 제공할 수 있다.
PCT/KR2016/012108 2015-10-26 2016-10-26 암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템 WO2017074036A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2018542073A JP6681475B2 (ja) 2015-10-26 2016-10-26 がん患者のゲノム塩基配列変異情報と生存情報を利用したカスタマイズ型の薬物選択方法及びシステム
EP16860219.1A EP3396573A4 (en) 2015-10-26 2016-10-26 METHOD AND SYSTEM FOR SELECTING A CUSTOMIZED MEDICINE USING GENOMIC NUCLEOTIDE SEQUENCE VARIATION INFORMATION AND CANCER PATIENT SURVIVAL INFORMATION
CN201680062975.4A CN108475300B (zh) 2015-10-26 2016-10-26 利用癌症患者的基因组碱基序列突变信息和生存信息的定制型药物选择方法及系统
US15/771,288 US20180312928A1 (en) 2015-10-26 2016-10-26 Method and system for selecting customized drug using genomic nucleotide sequence variation information and survival information of cancer patient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2015-0148717 2015-10-26
KR20150148717 2015-10-26
KR10-2016-0140346 2016-10-26
KR1020160140346A KR101949286B1 (ko) 2015-10-26 2016-10-26 암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템

Publications (2)

Publication Number Publication Date
WO2017074036A2 WO2017074036A2 (ko) 2017-05-04
WO2017074036A3 true WO2017074036A3 (ko) 2017-06-22

Family

ID=58631671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/012108 WO2017074036A2 (ko) 2015-10-26 2016-10-26 암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템

Country Status (1)

Country Link
WO (1) WO2017074036A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113851185B (zh) * 2021-11-29 2022-04-19 求臻医学科技（北京）有限公司 一种用于非小细胞肺癌患者免疫治疗的预后评估方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150021476A (ko) * 2013-08-19 2015-03-02 서울대학교산학협력단 약물 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 약물 선택 방법 및 시스템
JP2015089364A (ja) * 2013-11-07 2015-05-11 有限会社ジェノテックス 体細胞多重変異によるがん診断方法、がん医薬開発方法及びがん診断装置
KR101542529B1 (ko) * 2014-02-21 2015-08-06 (주)신테카바이오 대립유전자의 바이오마커 발굴방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150021476A (ko) * 2013-08-19 2015-03-02 서울대학교산학협력단 약물 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 약물 선택 방법 및 시스템
JP2015089364A (ja) * 2013-11-07 2015-05-11 有限会社ジェノテックス 体細胞多重変異によるがん診断方法、がん医薬開発方法及びがん診断装置
KR101542529B1 (ko) * 2014-02-21 2015-08-06 (주)신테카바이오 대립유전자의 바이오마커 발굴방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JERBY-ARNON ET AL.: "Predicting Cancer-specific Vulnerability via Data-driven Detection of Synthetic Lethality", CELL, vol. 158, 2014, pages 1199 - 1209, XP055376363 *
See also references of EP3396573A4 *
SZCZUREK ET AL.: "Synthetic Sickness or Lethality Points at Candidate Combination Therapy Targets in Glioblastoma", INTERNATIONAL JOURNAL OF CANCER, vol. 133, 2013, pages 2123 - 2132, XP055392022 *

Also Published As

Publication number Publication date
WO2017074036A2 (ko) 2017-05-04

Similar Documents

Publication Publication Date Title
SG10201807838SA (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
WO2017181202A3 (en) Methods for lung cancer detection
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
WO2014036387A3 (en) Methods for diagnosis and treatment of cancer
WO2015189345A3 (en) Compositions and methods for the diagnosis and treatment of bone fractures and disorders
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
WO2011088149A3 (en) Methods for predicting response of triple-negative breast cancer to therapy
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
EP4273782A3 (en) A system, device and a method for providing a therapy or a cure for cancer and other pathological states
PH12014502094A1 (en) Substituted nucleosides, nucleotides and analogs thereof
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
WO2009146460A3 (en) Methods for disease therapy
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
EP3396573A4 (en) METHOD AND SYSTEM FOR SELECTING A CUSTOMIZED MEDICINE USING GENOMIC NUCLEOTIDE SEQUENCE VARIATION INFORMATION AND CANCER PATIENT SURVIVAL INFORMATION
MD3393478T2 (ro) Terapie combinată
WO2016145308A3 (en) Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
MX2019002699A (es) Terapia genica para pacientes con anemia de fanconi.
WO2015093948A3 (en) Means and methods for typing a breast cancer patient and assigning therapy based on the typing
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201680062975.4

Country of ref document: CN

Ref document number: 2018542073

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15771288

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2016860219

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16860219

Country of ref document: EP

Kind code of ref document: A2